P Bramlage1, W März2,3,4, D Westermann5,6, B Weisser7, J H Wirtz8, U Zeymer9,10, P Baumgart11, G van Mark12, U Laufs13, B K Krämer2, T Unger14. 1. Institut für Pharmakologie und Präventive Medizin, Mahlow, Deutschland. peter.bramlage@ippmed.de. 2. Medizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakultät Mannheim, Universität Heidelberg, Heidelberg, Deutschland. 3. Klinisches Institut für Medizinische und Chemische Labordiagnostik, Medizinische Universität Graz, Graz, Österreich. 4. Synlab Akademie, synlab Holding Deutschland GmbH, Mannheim und Augsburg, Deutschland. 5. Klinik und Poliklinik für Allgemeine und Interventionelle Kardiologie, Universitätsklinikum Eppendorf, Hamburg, Deutschland. 6. Universitäres Herzzentrum Hamburg, Hamburg, Deutschland. 7. Institut für Sportwissenschaft, Christian-Albrechts-Universität zu Kiel, Kiel, Deutschland. 8. Kardiologische Gemeinschaftspraxis, Dinslaken, Deutschland. 9. Medizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Deutschland. 10. Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Deutschland. 11. Medizinische Klinik I, Clemenshospital Münster, Akad. LKH der Universität Münster, Münster, Deutschland. 12. Institut für Pharmakologie und Präventive Medizin, Mahlow, Deutschland. 13. Klinik für Innere Medizin III, Universitätsklinikum des Saarlands, Homburg/Saar, Deutschland. 14. CARIM School for Cardiovascular Diseases, Maastricht University, PO Box 616, 6200 MD, Maastricht, Niederlande.
Abstract
BACKGROUND: The multifactorial origin of cardiovascular diseases has led to polypharmacy in primary and secondary prophylaxis with evidence-based medications, such as statins, antihypertensive drugs and platelet aggregation inhibitors. The number of prescribed drugs correlates inversely to adherence and can lead to treatment failure. Fixed-dose combination drugs (polypills) could increase the medication adherence of patients, reduce risks and prevent cardiovascular events. METHODS: This review is based on publications that were retrieved from Medline (via PubMed) and The Cochrane Library. The clinical database ClinicalTrials.gov. was also considered. RESULTS: In the studies on primary prevention conducted to date, fixed-dose combinations showed a superior control of risk factors, e.g. hypertension and low-density lipoprotein (LDL) cholesterol compared to placebo and at least non-inferiority compared to usual care. In secondary prevention, the effect of the polypill is mostly on the reduction of blood pressure and LDL cholesterol in non-adherent patients; however, evidence that fixed-drug combinations reduce cardiovascular morbidity and mortality compared to standard therapy is lacking. CONCLUSION: The polypill can be considered as an alternative to polypharmacy after a risk-benefit assessment, especially in non-adherent patients. Ongoing studies are investigating the effect of the polypill on cardiovascular events. Current polypills are limited by the lack of sufficient dosages of the individual components to avoid overtreatment and undertreatment at the individual treatment level.
BACKGROUND: The multifactorial origin of cardiovascular diseases has led to polypharmacy in primary and secondary prophylaxis with evidence-based medications, such as statins, antihypertensive drugs and platelet aggregation inhibitors. The number of prescribed drugs correlates inversely to adherence and can lead to treatment failure. Fixed-dose combination drugs (polypills) could increase the medication adherence of patients, reduce risks and prevent cardiovascular events. METHODS: This review is based on publications that were retrieved from Medline (via PubMed) and The Cochrane Library. The clinical database ClinicalTrials.gov. was also considered. RESULTS: In the studies on primary prevention conducted to date, fixed-dose combinations showed a superior control of risk factors, e.g. hypertension and low-density lipoprotein (LDL) cholesterol compared to placebo and at least non-inferiority compared to usual care. In secondary prevention, the effect of the polypill is mostly on the reduction of blood pressure and LDL cholesterol in non-adherent patients; however, evidence that fixed-drug combinations reduce cardiovascular morbidity and mortality compared to standard therapy is lacking. CONCLUSION: The polypill can be considered as an alternative to polypharmacy after a risk-benefit assessment, especially in non-adherent patients. Ongoing studies are investigating the effect of the polypill on cardiovascular events. Current polypills are limited by the lack of sufficient dosages of the individual components to avoid overtreatment and undertreatment at the individual treatment level.
Authors: K M Venkat Narayan; George A Mensah; Stephen Sorensen; Yiling J Cheng; Frank Vinicor; Michael M Engelgau; David F Williamson Journal: Am J Prev Med Date: 2005-12 Impact factor: 5.043
Authors: F Malekzadeh; T Marshall; A Pourshams; M Gharravi; A Aslani; A Nateghi; M Rastegarpanah; M Khoshnia; S Semnani; R Salahi; G N Thomas; B Larijani; K K Cheng; R Malekzadeh Journal: Int J Clin Pract Date: 2010-08 Impact factor: 2.503
Authors: M Lafeber; D E Grobbee; I M Schrover; S Thom; R Webster; A Rodgers; F L J Visseren; M L Bots; W Spiering Journal: Int J Cardiol Date: 2014-12-03 Impact factor: 4.164
Authors: Nicholas J Wald; Johannes Michiel Luteijn; Joan K Morris; David Taylor; Peter Oppenheimer Journal: Eur J Epidemiol Date: 2016-03-05 Impact factor: 8.082
Authors: Angharad N de Cates; Matthew R B Farr; Nicola Wright; Morag C Jarvis; Karen Rees; Shah Ebrahim; Mark D Huffman Journal: Cochrane Database Syst Rev Date: 2014-04-16